Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michèle Boisdron-Celle

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Pharmacogenomics|October 13, 2012
Pharmacokinetic adaptation of 5-fluorouracil: where are we and where are we going?Michèle Boisdron-Celle
Therapie|July 10, 2016
[Not Available]Michèle Boisdron-Celle, Chantal Le Guellec,
Therapie|August 12, 2010
[Therapeutic drug monitoring of 5-fluorouracil after its administration in high-dose protocols]Michèle Boisdron-Celle, Chantal Le Guellec,
Therapie|June 22, 2007
[Detection of dihydropyrimidine dehydrogenase deficiency before treatment by fluoropyrimidines]Erick Gamelin, Michèle Boisdron-Celle, Alain Morel
Bulletin Du Cancer|February 24, 2006
[Oxaliplatin neurotoxicity]Laurence Gamelin, Michèle Boisdron-Celle, Alain Morel, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 20, 2005
An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practiceGaëlle Remaud, Michèle Boisdron-Celle, Catherine Hameline, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patientsElisabeth Rouits, Michèle Boisdron-Celle, Agnès Dumont, et al.
Neuromodulation : Journal of the International Neuromodulation Society|February 12, 2014
In vitro stability of low-concentration ziconotide alone or in admixtures in intrathecal pumpsDenis Dupoiron, Hélène Richard, Vincent Chabert-Desnot, et al.
Case Reports in Oncology|June 28, 2019
BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case ReportLaure Moisset, Judith Raimbourg, Sandrine Hiret, et al.
Molecular Cancer|July 8, 2011
Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cellsAgnes Basseville, Laurence Preisser, Sophie de Carné Trécesson, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Pharmacogenomics|October 13, 2012
Pharmacokinetic adaptation of 5-fluorouracil: where are we and where are we going?Michèle Boisdron-Celle
Therapie|July 10, 2016
[Not Available]Michèle Boisdron-Celle, Chantal Le Guellec,
Therapie|August 12, 2010
[Therapeutic drug monitoring of 5-fluorouracil after its administration in high-dose protocols]Michèle Boisdron-Celle, Chantal Le Guellec,
Therapie|June 22, 2007
[Detection of dihydropyrimidine dehydrogenase deficiency before treatment by fluoropyrimidines]Erick Gamelin, Michèle Boisdron-Celle, Alain Morel
Bulletin Du Cancer|February 24, 2006
[Oxaliplatin neurotoxicity]Laurence Gamelin, Michèle Boisdron-Celle, Alain Morel, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 20, 2005
An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practiceGaëlle Remaud, Michèle Boisdron-Celle, Catherine Hameline, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patientsElisabeth Rouits, Michèle Boisdron-Celle, Agnès Dumont, et al.
Neuromodulation : Journal of the International Neuromodulation Society|February 12, 2014
In vitro stability of low-concentration ziconotide alone or in admixtures in intrathecal pumpsDenis Dupoiron, Hélène Richard, Vincent Chabert-Desnot, et al.
Case Reports in Oncology|June 28, 2019
BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case ReportLaure Moisset, Judith Raimbourg, Sandrine Hiret, et al.
Molecular Cancer|July 8, 2011
Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cellsAgnes Basseville, Laurence Preisser, Sophie de Carné Trécesson, et al.
Pageof 3